Evidence map›Paper›PMID 14761105›Full record

ReviewCanadian family physician Medecin de famille canadien2004

Current status of PSA screening. Early detection of prostate cancer.

Tom Pickles

Abstract readReview
PubMed Full text at PMC
In one paragraph

Review in Canadian family physician Medecin de famille canadien, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Sexual consequences of prostate cancer treatment.Canadian family physician Medecin de famille canadien · 2005
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Tom PicklesGenito-Urinary Tumour Group, British Columbia Cancer Agency, Vancouver.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo update current evidence for prostate-specific antigen (PSA) screening for prostate cancer and to give readers some practical information to discuss with patients. QUALITY OF EVIDENCE A MEDLINE: search revealed only three randomized studies, two of which are incomplete. Several controlled non-randomized studies were found. MAIN MESSAGE: Two ongoing studies have not yet reported survival data, but have added to evidence for screening intervals. One Canadian randomized study has been criticized for its design and conclusions. Non-randomized studies suggest that screening effectively identifies serious cancers and leads to earlier diagnosis. Mortality from prostate cancer has been falling in most western countries since 1992. This cannot be explained by PSA screening, which would probably not produce survival benefit until at least 10 years after its unofficial introduction in about 1990.

conclusionIndirect evidence suggests that all men older than 45 with at least a 10-year life expectancy should be informed of the potential benefits and drawbacks of PSA screening so they can make an informed decision on whether to have the test.

Indexed as

Mass ScreeningAgedDiagnosis, DifferentialEvidence-Based MedicineHumansLife ExpectancyMaleMiddle AgedPatient Education as TopicPrognosisProstate-Specific AntigenProstatic NeoplasmsRandomized Controlled Trials as TopicSurvival AnalysisProstate-Specific Antigen

Identifiers

PMID14761105
PMCPMC2214499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.